Skip to main content
Top
Published in: Breast Cancer Research 1/1999

01-12-1999 | Commentary

Do we now have a relevant animal model for breast cancer?

Authors: Barry Gusterson, Beatrice Howard, Tim Crook, Barbara Tennent

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Recent advances in manipulating targeted genes in a tissue-specific manner have opened the way to the development of relevant mouse models for the molecular dissection of the events leading to breast cancer. However, when judging the appropriateness of any given mouse model, it is important to remember that breast cancer comprises a heterogeneous group of diseases characterized by different sets of genetic mutations, histopathological types and metastatic potentials, often within the same primary tumour mass. It is unlikely that any single mouse model will be able to mimic all these aspects of human breast cancer but this does not invalidate their use in studying specific aspects of the disease. Mouse models are particularly valuable for defining the molecular pathways participating in mammary epithelial cell transformation and disease progression, for identifying modifier genes that affect penetrance of the manipulated gene and for testing various therapeutic and preventative approaches. The paper by Xu et al [1] in a recent edition of Nature Genetics describes a new model that offers promise in several respects. …
Literature
1.
go back to reference Xu X, Wagner K-U, Larson D, et al: Conditional knockout of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet. 1999, 22: 37-43. 10.1038/8743.CrossRefPubMed Xu X, Wagner K-U, Larson D, et al: Conditional knockout of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet. 1999, 22: 37-43. 10.1038/8743.CrossRefPubMed
2.
go back to reference Callahan R: MMTV-induced mutations in mouse mammary tumours: Their potential relevance to human breast cancer. Breast Cancer Res Treatment. 1996, 39: 33-44.CrossRef Callahan R: MMTV-induced mutations in mouse mammary tumours: Their potential relevance to human breast cancer. Breast Cancer Res Treatment. 1996, 39: 33-44.CrossRef
3.
go back to reference Cardiff RD, Munn RJ: The histopathology of transgenes and knockouts in the mammary gland. Advan Oncobiol. 1998, 2: 177-202.CrossRef Cardiff RD, Munn RJ: The histopathology of transgenes and knockouts in the mammary gland. Advan Oncobiol. 1998, 2: 177-202.CrossRef
5.
go back to reference Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984, 38: 627-637.CrossRefPubMed Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984, 38: 627-637.CrossRefPubMed
6.
go back to reference Webster MA, Hutchinson JN, Rauh MJ, et al: Requirement for both Shc and phosphatidylinositol 3' kinase signalling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol. 1998, 18: 2344-2359.CrossRefPubMedPubMedCentral Webster MA, Hutchinson JN, Rauh MJ, et al: Requirement for both Shc and phosphatidylinositol 3' kinase signalling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol. 1998, 18: 2344-2359.CrossRefPubMedPubMedCentral
7.
go back to reference Kuhn R, Schwenk F, Aguet M, Rajewsky K: Inducible gene targeting in mice. Science. 1995, 269: 1427-1429.CrossRefPubMed Kuhn R, Schwenk F, Aguet M, Rajewsky K: Inducible gene targeting in mice. Science. 1995, 269: 1427-1429.CrossRefPubMed
8.
go back to reference Tirkkonen M, Johannsson O, Agnarsson BA, et al: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997, 57: 1222-1227.PubMed Tirkkonen M, Johannsson O, Agnarsson BA, et al: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997, 57: 1222-1227.PubMed
9.
go back to reference Crook T, Brooks LA, Crossland S, et al: Frequent p53 mutations without a mutator phenotype in BRCA2-associated breast tumours. Oncogene. 1998, 17: 1681-1689. 10.1038/sj/onc/1202106.CrossRefPubMed Crook T, Brooks LA, Crossland S, et al: Frequent p53 mutations without a mutator phenotype in BRCA2-associated breast tumours. Oncogene. 1998, 17: 1681-1689. 10.1038/sj/onc/1202106.CrossRefPubMed
10.
go back to reference Smith PD, Crossland S, Parker G, et al: Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene. 1999, 18: 2451-2459. 10.1038/sj/onc/1202565.CrossRefPubMed Smith PD, Crossland S, Parker G, et al: Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene. 1999, 18: 2451-2459. 10.1038/sj/onc/1202565.CrossRefPubMed
11.
go back to reference Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed
12.
go back to reference Cormier RT, Hong KH, Halberg RB, et al: Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet. 1997, 17: 88-91.CrossRefPubMed Cormier RT, Hong KH, Halberg RB, et al: Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet. 1997, 17: 88-91.CrossRefPubMed
13.
go back to reference Drebin JA, Link VC, Greene MI: Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. 1988, 2: 273-277 .PubMed Drebin JA, Link VC, Greene MI: Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. 1988, 2: 273-277 .PubMed
Metadata
Title
Do we now have a relevant animal model for breast cancer?
Authors
Barry Gusterson
Beatrice Howard
Tim Crook
Barbara Tennent
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine